Phase I study of continuous-infusion PALA and 5-FU

B. Ardalan, D. Jamin, H. N. Jayaram, C. A. Presant

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Eighteen patients with malignancies refractory to conventional forms of therapy were treated with 5-day continuous infusions of PALA and 5-FU. PALA was administered at a dose of 940 mg/m2/day. 5-FU was initially given at a dose of 180 mg/m2/day and was incrementally increased to 325 mg/m2/day. The courses were repeated every 3-4 weeks. Mucositis and diarrhea were the dose-limiting toxic effects. Other reversible side effects included grade 2 skin rashes and nausea and vomiting. Peak plasma PALA concentrations were approximately 20 μM and occurred in conjunction with a maximum depression of leukocyte-L-aspartate transcarbamylase (ATCase) activity to 10% of baseline. Therapeutic responses occurred in one of the 13 patients with colon carcinoma and in one patient with mammary carcinoma. Responses could not be correlated with leukocyte ATCase depression. Recent data indicate that low doses of PALA (250 mg/m2) might be equally as effective in inhibiting leukocyte ATCase activity as the doses used in this study. A phase II trial has been designed at this institution employing the above doses of PALA in conjuction with escalating doses of 5-FU.

Original languageEnglish (US)
Pages (from-to)531-534
Number of pages4
JournalCancer Treatment Reports
Volume68
Issue number3
StatePublished - 1984
Externally publishedYes

Fingerprint

NSC 224131
Fluorouracil
Aspartate Carbamoyltransferase
Leukocytes
Mucositis
Poisons
Exanthema
Aspartic Acid
Nausea
Vomiting
Diarrhea
Colon
Breast Neoplasms
Carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ardalan, B., Jamin, D., Jayaram, H. N., & Presant, C. A. (1984). Phase I study of continuous-infusion PALA and 5-FU. Cancer Treatment Reports, 68(3), 531-534.

Phase I study of continuous-infusion PALA and 5-FU. / Ardalan, B.; Jamin, D.; Jayaram, H. N.; Presant, C. A.

In: Cancer Treatment Reports, Vol. 68, No. 3, 1984, p. 531-534.

Research output: Contribution to journalArticle

Ardalan, B, Jamin, D, Jayaram, HN & Presant, CA 1984, 'Phase I study of continuous-infusion PALA and 5-FU', Cancer Treatment Reports, vol. 68, no. 3, pp. 531-534.
Ardalan B, Jamin D, Jayaram HN, Presant CA. Phase I study of continuous-infusion PALA and 5-FU. Cancer Treatment Reports. 1984;68(3):531-534.
Ardalan, B. ; Jamin, D. ; Jayaram, H. N. ; Presant, C. A. / Phase I study of continuous-infusion PALA and 5-FU. In: Cancer Treatment Reports. 1984 ; Vol. 68, No. 3. pp. 531-534.
@article{4b175bae560f40e5a6f1b627e57e7c1d,
title = "Phase I study of continuous-infusion PALA and 5-FU",
abstract = "Eighteen patients with malignancies refractory to conventional forms of therapy were treated with 5-day continuous infusions of PALA and 5-FU. PALA was administered at a dose of 940 mg/m2/day. 5-FU was initially given at a dose of 180 mg/m2/day and was incrementally increased to 325 mg/m2/day. The courses were repeated every 3-4 weeks. Mucositis and diarrhea were the dose-limiting toxic effects. Other reversible side effects included grade 2 skin rashes and nausea and vomiting. Peak plasma PALA concentrations were approximately 20 μM and occurred in conjunction with a maximum depression of leukocyte-L-aspartate transcarbamylase (ATCase) activity to 10{\%} of baseline. Therapeutic responses occurred in one of the 13 patients with colon carcinoma and in one patient with mammary carcinoma. Responses could not be correlated with leukocyte ATCase depression. Recent data indicate that low doses of PALA (250 mg/m2) might be equally as effective in inhibiting leukocyte ATCase activity as the doses used in this study. A phase II trial has been designed at this institution employing the above doses of PALA in conjuction with escalating doses of 5-FU.",
author = "B. Ardalan and D. Jamin and Jayaram, {H. N.} and Presant, {C. A.}",
year = "1984",
language = "English (US)",
volume = "68",
pages = "531--534",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Phase I study of continuous-infusion PALA and 5-FU

AU - Ardalan, B.

AU - Jamin, D.

AU - Jayaram, H. N.

AU - Presant, C. A.

PY - 1984

Y1 - 1984

N2 - Eighteen patients with malignancies refractory to conventional forms of therapy were treated with 5-day continuous infusions of PALA and 5-FU. PALA was administered at a dose of 940 mg/m2/day. 5-FU was initially given at a dose of 180 mg/m2/day and was incrementally increased to 325 mg/m2/day. The courses were repeated every 3-4 weeks. Mucositis and diarrhea were the dose-limiting toxic effects. Other reversible side effects included grade 2 skin rashes and nausea and vomiting. Peak plasma PALA concentrations were approximately 20 μM and occurred in conjunction with a maximum depression of leukocyte-L-aspartate transcarbamylase (ATCase) activity to 10% of baseline. Therapeutic responses occurred in one of the 13 patients with colon carcinoma and in one patient with mammary carcinoma. Responses could not be correlated with leukocyte ATCase depression. Recent data indicate that low doses of PALA (250 mg/m2) might be equally as effective in inhibiting leukocyte ATCase activity as the doses used in this study. A phase II trial has been designed at this institution employing the above doses of PALA in conjuction with escalating doses of 5-FU.

AB - Eighteen patients with malignancies refractory to conventional forms of therapy were treated with 5-day continuous infusions of PALA and 5-FU. PALA was administered at a dose of 940 mg/m2/day. 5-FU was initially given at a dose of 180 mg/m2/day and was incrementally increased to 325 mg/m2/day. The courses were repeated every 3-4 weeks. Mucositis and diarrhea were the dose-limiting toxic effects. Other reversible side effects included grade 2 skin rashes and nausea and vomiting. Peak plasma PALA concentrations were approximately 20 μM and occurred in conjunction with a maximum depression of leukocyte-L-aspartate transcarbamylase (ATCase) activity to 10% of baseline. Therapeutic responses occurred in one of the 13 patients with colon carcinoma and in one patient with mammary carcinoma. Responses could not be correlated with leukocyte ATCase depression. Recent data indicate that low doses of PALA (250 mg/m2) might be equally as effective in inhibiting leukocyte ATCase activity as the doses used in this study. A phase II trial has been designed at this institution employing the above doses of PALA in conjuction with escalating doses of 5-FU.

UR - http://www.scopus.com/inward/record.url?scp=0021241909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021241909&partnerID=8YFLogxK

M3 - Article

VL - 68

SP - 531

EP - 534

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 3

ER -